Weiguo Qing
Shanghai University of Medicine and Health Sciences(CN)
Publications by Year
Research Areas
Liver physiology and pathology, PI3K/AKT/mTOR signaling in cancer, Lung Cancer Treatments and Mutations, Cancer, Hypoxia, and Metabolism, Hepatocellular Carcinoma Treatment and Prognosis
Most-Cited Works
- → Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy(2006)700 cited
- → Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy(2014)151 cited
- → A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo(2006)146 cited
- → Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer(2014)133 cited
- → Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models(2014)119 cited
- → Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation(2016)37 cited
- → Identification of novel, potent and selective inhibitors of Polo-like kinase 1(2011)33 cited
- → Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor(2019)22 cited
- → Kinetics of the Reaction of a Potential Chemopreventive Agent, 2,6-Dithiopurine, and Its Major Metabolite, 2,6-Dithiouric Acid, with Multiple Classes of Electrophilic Toxicants(1996)13 cited
- → Mixed effects of 2,6-dithiopurine against cyclophosphamide mediated bladder and lung toxicity in mice(1998)12 cited